Hendrick, Alex M., Mitchell, Murray D. and Harris, Adrian L. (1988) Plasma prostaglandins in lung cancer. European Journal of Cancer and Clinical Oncology, 246: 1069-1071. doi:10.1016/0277-5379(88)90161-7
Plasma levels of three stable prostaglandin (PG) metabolites were measured in 29 patients with lung cancer. The mean level of 6-keto-PGF1α, the hydrolysis product of prostacyclin was significantly elevated in cancer patients compared to a control group with non-malignant respiratory disorders, although an overlap in values between the groups was seen. Levels correlated inversely with survival and showed a significant fall in 14 patients with tumour regression. The mean level of 11-deoxy-3, 14-dihydro-15-keto-11,16-cyclo-prostaglandin E2 was also significantly elevated in cancer patients, but did not correlate with tumour response. 13,14-Dihydro-15-keto-prostaglandin F2α levels did not differ in lung cancer patients and controls. Contrary to previous reports we could not support a role for the metabolites of PGE2 and PGF2α as tumour markers in lung cancer but plasma 6-keto-PGF1α should be further evaluated in this regard.